DermTech, Inc.

DermTech, Inc. (Nasdaq: DMTK) is a precision dermatology company that reached the public markets through its 2019 merger with Constellation Alpha Capital Corp, a blank-check company sponsored by Constellation Alpha Management. The SPAC completed its initial public offering in 2017, targeting the healthcare and life sciences sector. DermTech develops non-invasive genomic diagnostics for skin conditions, with its lead product being an adhesive patch-based test for melanoma detection. The 10-Q filed August 13, 2019, with accession number 0001193125-19-219949, represents an early post-merger quarterly disclosure as the combined entity began trading under the DMTK ticker. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time SPAC data on DermTech and hundreds of other transactions.